Areas of expertise

• Infectious Diseases 110309
• Cellular Immunology 110704
• Immunology 1107
• Medical Molecular Engineering Of Nucleic Acids And Proteins 100403
• Cellular Interactions (Incl. Adhesion, Matrix, Cell Wall) 060106
• Medical Virology 110804
• Immunology Not Elsewhere Classified 110799

Research interests

Available student projects

Publications

• Li, Z, Roy, S & Ranasinghe, C 2022, 'Evaluation of Innate Lymphoid Cells and Dendritic Cells Following Viral Vector Vaccination', in Alejandro Brun (ed.), Vaccine Technologies for Veterinary Viral Diseases, Humana, New York, NY, New York, NY, pp. 137-153.
• Watterson, D, Wijesundara, D, Modhiran, N et al. 2021, 'Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2', Clinical and Translational Immunology, vol. 10, no. 4, pp. 1-21.
• Chappell, K, Mordant, F, Li, Z et al. 2021, 'Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial', The Lancet Infectious Diseases, vol. 21, no. 10, pp. 1-13.
• Li, Z, Roy, S & Ranasinghe, C 2021, 'IL-13R alpha 2 Regulates the IL-13/IFN-gamma Balance during Innate Lymphoid Cell and Dendritic Cell Responses to Pox Viral Vector-Based Vaccination', Vaccines, vol. 9, no. 5, pp. 1-21.
• Isaacs, A, Li, Z, Cheung, S et al. 2021, 'Adjuvant selection for influenza and RSV prefusion subunit vaccines', Vaccines, vol. 9, no. 2, pp. 1-14.
• Deimel, L, Li, Z, Roy, S et al. 2021, 'STAT3 determines IL-4 signalling outcomes in na�ve T cells', Scientific Reports, vol. 11.
• Li, Z, Khanna, M, Grimley, S et al. 2020, 'Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques', Scientific Reports, vol. 10, no. 1.
• Roy, S, Liu, H, Jaeson, M et al. 2020, 'Unique IL-13Rα2/STAT3 mediated IL-13 regulation detected in lung conventional dendritic cells, 24 h post viral vector vaccination', Scientific Reports, vol. 10, no. 1017, pp. 1-14.
• Mekonnen, Z, Grubor-Bauk, B, Masavuli, M et al. 2019, 'Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection', Frontiers in Cellular and Infection Microbiology, vol. 9, no. 91, pp. 1-8.
• Li, Z, Jackson, R & Ranasinghe, C 2019, 'A hierarchical role of IL-25 in ILC development and function at the lung mucosae following viral-vector vaccination', Vaccine: X, vol. 2, pp. 1-9.
• Khanna M., Jackson R.J., Alcantara S., Amarasena T.H., Li Z., Kelleher A.D., Kent S.J. and RANASINGHE C. 2019 Mucosal and systemic SIV-specific cytotoxic CD4(+) T cell hierarchy in protection following intranasal/intramuscular recombinant pox-viral vaccination of pigtail macaques. Scientific Reports. 2019;9(1):5661. Epub 2019/04/07 06:00. PubMed PMID: 30952887
• Roy S., Jaeson M., Li Z. Mahboob S., Jackson R.J., Grubor-Bauk B., Wijesundara D.K., Gowans E.J., RANASINGHE C. 2019 'Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes', Vaccine, vol. 37, no. 10, pp. 1266-1276.
• Khanna M, RANASINGHE C, Browne AM, Li JP, Vlodavsky I, Parish CR. 2019 Is host heparanase required for the rapid spread of heparan sulfate binding viruses? Virology. 529:1-6.
• Hamid M.A., Jackson R.J., Roy S., Khanna M, and RANASINGHE C. 2018, 'Unexpected involvement of IL-13 signalling via a STAT6 independent mechanism during murine IgG2a development following viral vaccination', European Journal of Immunology, vol. 48, no. 7, pp. 1153-1163.
• Li Z., Jackson R.J., RANASINGHE C. 2018 Vaccination route can significantly alter the innate lymphoid cell subsets: A feedback between IL-13 and IFN-?. NPJ Vaccines. 12;3:10.
• RANASINGHE C, Roy S, Li Z, Khanna M and Jackson RJ. IL-4 and IL-13 receptors. 2018 Published In: Encyclopedia of Signaling Molecules, 2nd Edition. Springer publication, edited by Sangdun Choi (Invited book chapter) https://doi.org/10.1007/978-3-319-67199-4.
• Wijesundara DK, Gummow J, Li Y, Yu W, Quah BJ, RANASINGHE C, Torresi J, Gowans EJ, Grubor-Bauk B. 2018 Induction of genotype-cross reactive, hepatitis C virus-specific cell mediuated immunity in DNA-vaccinated mice J Virol. pii: JVI.02133-17. doi: 10.1128/JVI.02133-17
• Khanna M, RANASINGHE C, Jackson R, Parish CR. 2017 'Heparan sulfate as a receptor for poxvirus infections and as a target for antiviral agents', Journal of General Virology, vol. 98, no. 10, pp. 2556-2568.
• Sedger, L, RANASINGHE, C, McDermott, M et al 2017, 'Therapeutic Antibody-Based Drugs in the Treatment of Human Inflammatory Disorders', in Krassimir Metodiev (ed.), Immunotherapy - Myths, Reality, Ideas, Future, InTech Open Access Publisher, USA, pp. 224-270pp.
• Townsend, D, Trivedi, S, Jackson, R and RANASINGHE C 2017, 'Recombinant fowlpox virus vector-based vaccines: Expression kinetics, dissemination and safety profile following intranasal delivery', Journal of General Virology, vol. 98, no. 3, pp. 496-505pp.
• Trivedi, S, Neeman, T, Jackson, RJ, Ranasinghe R, Jack C, RANASINGHE C 2015, 'Identification of biomarkers to measure HIV-specific mucosal and systemic CD8+ T-cell immunity using single cell Fluidigm 48.48 Dynamic arrays', Vaccine, vol. 33, no. 51, pp. 7315-7327.
• Trivedi, S & RANASINGHE, C 2015, 'The influence of immunization route, tissue microenvironment, and cytokine cell milieu on HIV-specific CD8+ T cells measured using Fluidigm Dynamic arrays', PLOS ONE (Public Library of Science), vol. 10, no. 5, pp. 1-21.
• Ravichandran, J, Jackson, R, Trivedi, S and RANASINGHE, C. 2015, 'IL-17A Expression in HIV-Specific CD8 T Cells Is Regulated by IL-4/IL-13 Following HIV-1 Prime-Boost Immunization', Journal of Interferon and Cytokine Research, vol. 35, no. 3, pp. 176-185.
• DeRose R., S. J. Kent and RANASINGHE, C (2014). Prime-boost vaccination: Impact on the HIV vaccine field. Novel approaches and satrategies for biologics, vaccines and cancer therapies, Elsevier publication edited by Drs. Manmohan Singh and Maya Salnikova. 2014
• Jackson, R, Boyle, D & RANASINGHE C 2014, 'Progresses in DNA-based heterologous prime-boost immunization strategies.', in Monica Rinaldi, Daniela Fioretti, Sandra Iurescia (ed.), DNA Vaccines, Springer New York, New York, pp. 61-90.
• Jackson, RJ, Worley, M, Trivedi, S, RANASINGHE, C. 2014, 'Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy', Vaccine, vol. 32, no. 43, pp. 5703-5714.
• RANASINGHE, C, Trivedi, S, Wijesundara, DK, Jackson RJ. 2014, 'IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants', Cytokine and Growth Factor Reviews, vol. 25, no. 4, pp. 437-442.
• Sedger, L, Seddiki, N & RANASINGHE, C 2014, 'Cytokines and cytokine receptors as immunotherapeutics: humble beginnings and exciting futures', Cytokine and Growth Factor Reviews, vol. 25, no. 4, pp. 351-353.
• Quah, B, Wijesundara, D, RANASINGHE, C et al 2014, 'The use of fluorescent target arrays for assessment of T cell responses in vivo', Journal of Visualized Experiments, no. 88, pp. e51627-.
• Trivedi, S, Jackson, RJ & RANASINGHE, C 2014, 'Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidity', Virology, vol. 468, pp. 479-489.
• RANASINGHE, C 2014, 'New advances in mucosal vaccination', Immunology Letters, vol. 161, no. 2, pp. 204-206.
• Wijesundara, D, Xi, Y & RANASINGHE, C 2014, 'Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for the rapeutics and vaccine design', Frontiers in Immunology, vol. 5, no. August, pp. 1-7.
• Quah, B, Wijesundara, D, RANASINGHE, C, Parish, CR 2013, 'Fluorescent target array T helper assay: A multiplex flow cytometry assay to measure antigen-specific CD4+ T cell-mediated B cell help in vivo', Journal of Immunological Methods, vol. 387, no. 1-2, pp. 181-190.
• RANASINGHE, C., Trivedi, S, Stambas, J and Jackson RJ 2013, 'Unique IL-13Ralpha2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8+ T-cell avidity and protective immunity', Mucosal Immunology, vol. 6, pp. 1068-1080.
• Trivedi, S., Jackson, R.J. and RANASINGHE C. 2013. Interleukin-3 and Granulocyte-Macrophage Colony-Stimulating Factor Expression, a Biomarker of Memory CD8+ T Cell Immunity and Vaccine Efficacy. Journal of Vaccines and Vaccination 3:1000166 (open access journal).
• Wiede, F., P. D. Fromm, I. Comerford, E. Kara, J. Bannan, W. Schuh, C. RANASINGHE, D. Tarlinton, T. Winkler, S. R. McColl, and H. Korner. 2013. CCR6 is transiently upregulated on B cells after activation and modulates the germinal center reaction in the mouse. Immunol Cell Biol vol. 91, no. 5, pp. 335-339.
• Wijesundara, D. K., Tscharke, D. C., Jackson, R. J. and RANASINGHE, C. 2013, 'Reduced Interleukin-4 Receptor alpha Expression on CD8+ T Cells Correlates with Higher Quality Anti-Viral Immunity', PLoS ONE, vol. 8, no. 1, p. e55788.
• Wijesundara, DK, Jackson, RJ, Tscharke, DC and RANASINGHE, C. 2013, 'IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8+ T cell avidity following HIV-1 recombinant pox viral vaccination', Vaccine, vol. 31, no. 41, pp. 4548-4555.
• Hamid M.A., Jackson R.J., Roy S., Khanna M, and RANASINGHE C. 2018 Unexpected involvement of IL-13 signalling via a STAT6 independent mechanism, during IgG2a development Following viral vaccination. European Journal of Immunology Jul;48(7):1153-1163.
• Wijesundara, D & RANASINGHE, C 2012, 'Prime boost regimens for enhancing immunity: magnitude, quality of mucosal and systemic gene vaccines', in J Thalhamer, R Weiss, S Scheiblhofer (ed.), Gene Vaccines, Landes Bioscience/Springer Science+Business Media, New York, pp. 183-204.
• Xi, Y, Day, S, Jackson, RJ, RANASINGHE, C. 2012, 'Role of novel type I interferon epsilon in viral infection and mucosal immunity', Mucosal Immunology, vol. 5, no. 6, pp. 610-622.
• Quah, B., Wijesundara, D.K., RANASINGHE, C. and Parish, C.R. 2012, Fluorescent target array killing assay: A multiplex cytotoxic T-cell assay to measure detailed T-cell antigen specificity and avidity in vivo. Cytometry A, Vol 81 (8), 679-90.
• RANASINGHE, C., and Trivedi. S. 2011. Heterologous prime-boost immunization: HIV-specific systemic/mucosal immunity, cytokine milieu and CD8+ T cell avidity. Novel Approaches to Vaccine Research by Research Snapshot, Transworld Research Network. Ed: K.L. Hofferon
• RANASINGHE, C., Eyers, F., Stambas, J. et al 2011, 'A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations', Vaccine, vol. 29, no. 16, pp. 3008-3020.
• Wijesundara, DK., Jackson, RJ., Ramshaw, IA. and RANASINGHE, C. 2011, 'Human immunodeficiency virus-1 vaccine design: where do we go now?', Immunology and Cell Biology, vol. 89, pp. 367-374.
• Sutherland D.B., RANASINGHE C., Regner M., Phipps S., Matthaei K.I., Day S.L., Ramshaw I.A. 2010. Evaluating vaccinia virus cytokine co-expression in TLR GKO mice. Immunol Cell Biol Dec 2010:21.
• RANASINGHE, C & Ramshaw, I 2009, 'Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity', European Journal of Immunology, vol. 39, pp. 1819-1830.
• RANASINGHE, C & Ramshaw, I 2009, 'Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity', Expert Review of Vaccines, vol. 8, no. 9, pp. 1171-1181.
• Day, S. L., I. A. Ramshaw, A. J. Ramsay, and C. RANASINGHE. 2008. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. J Immunol 180:7158-7166
• RANASINGHE, C., S. J. Turner, C. McArthur, D. B. Sutherland, J. H. Kim, P. C. Doherty, and I. A. Ramshaw. 2007. Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 178:2370-2379.
• Harrison, J. M., E. M. Bertram, D. B. Boyle, B. E. Coupar, C. RANASINGHE, and I. A. Ramshaw. 2006. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine. Vaccine 24:6867-6874.
• Thomson, S. A., A. B. Jaramillo, M. Shoobridge, K. J. Dunstan, B. Everett, C. RANASINGHE, S. J. Kent, K. Gao, J. Medveckzy, R. A. Ffrench, and I. A. Ramshaw. 2005. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine 23:4647-4657
• RANASINGHE, C., J. C. Medveczky, D. Woltring, K. Gao, S. Thomson, B. E. Coupar, D. B. Boyle, A. J. Ramsay, and I. A. Ramshaw. 2006. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 24:5881-5895.
• Kent, S. J., C. J. Dale, C. RANASINGHE, I. Stratov, R. De Rose, S. Chea, D. C. Montefiori, S. Thomson, I. A. Ramshaw, B. E. Coupar, D. B. Boyle, M. Law, K. M. Wilson, and A. J. Ramsay. 2005. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 23:5009-5021.
• Thomson SA, Jaramillo AB, Shoobridge M, Dunstan K. J., Everett B., RANASINGHE C, Kent SJ, Gao K, Medveckzy J, Ffrench RA, and Ramshaw. IA;, 2005, 'Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use', Vaccine, vol. 23, pp. 4647-4657.
• Dale, C. J., R. De Rose, K. M. Wilson, H. A. Croom, S. Thomson, B. E. Coupar, A. Ramsay, D. F. Purcell, R. Ffrench, M. Law, S. Emery, D. A. Cooper, I. A. Ramshaw, D. B. Boyle, S. J. Kent, and AustralianThai Vaccine Consortimum. 2004. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine 23:188-197
• Skinner, M. A., A. J. Ramsay, G. S. Buchan, D. L. Keen, C. RANASINGHE, L. Slobbe, D. M. Collins, G. W. de Lisle, and B. M. Buddle. 2003. A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology 108:548-555
• RANASINGHE, C., and R. J. Akhurst. 2002. Matrix assisted laser desorption ionisation time of flight mass spectrometry (MALDI-TOF MS) for detecting novel Bt toxins. J Invertebr Pathol 79:51-58

Projects and Grants

Grants information is drawn from ARIES. To add or update Projects or Grants information please contact your College Research Office.

• Rapid Response Pipeline for Stabilized Subunit Vaccines (Secondary Investigator)
• Env-Gag MicroCubes as a vaccine targeting broadly neutralising and mucosal responses (Secondary Investigator)
• Mucosal human immunodeficiency virus vaccine late pre-clinical evaluation (Primary Investigator)
• Advancement of a novel HIV vaccine for pre-clinical evaluation (DTF230) (Primary Investigator)
• Preclinical evaluation of a novel mucosal HIV-1 vaccine strategy (Primary Investigator)
• Evaluation of a novel mucosal vaccine delivery device (Primary Investigator)
• Pre-clinical evaluation of a novel mucosal HIV-1 vaccine strategy (Primary Investigator)
• Evaluation of a novel mucosal vaccine delivery device (Primary Investigator)
• Validation of an effective HIV vaccine for pre-clinical evaluation (Primary Investigator)
• EcoHIV, a convenient, biosafety Level 2, mouse model for animal testing of HIV vaccines and anti-retroviral drugs (Secondary Investigator)
• Design an effective poxvirus based vaccine for HIV-1 by modulating immune cell milieu using an IL-10 antagonist (Primary Investigator)
• A novel vaccine cytokine trap technology to induce robust mucosal/systemic immunity (Primary Investigator)
• Use of cytokine trap technology to augment T cell avidity against HIV vaccine antigens (Primary Investigator)
• A novel strategy to enhance T cell-mediated immunity to vaccine antigens (Primary Investigator)
• Enhancement of mucosal immunity and CTL avidity against HIV-1 (Primary Investigator)